# Chris Gordon

> Chris Gordon is a private equity investor at Bain Capital backing Biotechnology and Pharmaceutical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Bain Capital](https://shizune.co/investors/profile/bain-capital)
- Location: Boston, United States
- Total investments: 3
- Last investment: Oct 2025
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chris-g-11511a1aa/

Chris Gordon is a private equity investor at Bain Capital in Boston focused on Biotechnology and Pharmaceutical. Chris Gordon

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Medical Device | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 2 | 67% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kailera Therapeutics | Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. | $600M | Series B | Oct 14, 2025 |  |
| Kestra Medical Technologies, Inc. | Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients. | $196M | Private Equity | Jul 24, 2024 |  |
| Cerevel Therapeutics | Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stageinvestigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder. | $350M | Private Equity | Oct 26, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 1 deal together
- [CPP Investments](https://shizune.co/investors/profile/canada-pension-plan-investment-board) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 1 deal together

## About Bain Capital

VC Fund · Boston, United States

Bain Capital is a multi-asset alternative investment firm with assets under management and operates business units that create value through private equity, public equity, credit, and venture capital across multiple sectors and industries.

5 contacts available at Bain Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Amanda Zajac | Investor | https://shizune.co/investors/profile/amanda-zajac-6a8e |
| David Humphrey | Partner and Co-Head of North America Private Equity | https://shizune.co/investors/profile/david-humphrey |
| Elena Lieskovska | Partner on the Special Situations team | https://shizune.co/investors/profile/elena-lieskovska |
| Adam Koppel | Managing Director | https://shizune.co/investors/profile/adam-koppel |
| Ajay Mantha | Director | https://shizune.co/investors/profile/ajay-mantha |

## Similar investors

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

## FAQ

### What does Chris Gordon invest in?

Chris Gordon invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Private Equity and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Gordon last invest?

The most recent investment recorded for Chris Gordon closed in Oct 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co